Biopharma Value Chain · US / HK / A-Share · Investment Map

Understand Biopharma in One Map:
A Decision Map Across Three Markets from Reagents & Raw Materials to Innovative Drugs Going Global

The value of this chain is determined by two variables: "clinical data" and "cash flow". This map details 26 companies across the US, HK, and A-Share markets along the path of "Upstream Tools & Raw Materials → Midstream CXO & Pharma → Downstream Commercial Distribution", focusing on three main themes: the global GLP-1 weight loss drug supercycle, the License-out going global of Chinese innovative drugs (total transaction volume of ~$135.7 billion in 2025), and the recovery of CXO "shovel sellers". Designed to assist, not replace, your decisions.

Data Benchmark: Early July 2026 · Market and clinical progress figures are approximate; please verify real-time data and latest announcements before placing orders
2025 China Innovative Drug License-out
≈$135.7B
Record total value, 157 deals, upfront payments >$7B
Global Weight Loss Drug Market
Hundreds of Billions USD
Eli Lilly + Novo Nordisk duopoly; oral GLP-1 accelerates expansion
Semaglutide Patent in China
Expires in 2026
Benefits domestic biosimilars & APIs volume growth
WuXi AppTec Backlog
≈¥60 Billion
~1.3x of previous year's revenue, Q1 net profit +71.7%
Policy Positioning Upgrade
Emerging Pillar Industry
2026 Government Work Report defines biopharma this way for the first time
01

Value Chain Map: Drugs Flow Right, R&D Investments & Orders Flow Left

The key to understanding this value chain lies in two directions: Product Flow delivers from upstream to downstream (reagents/raw materials → R&D & manufacturing services → drugs/devices → patients); Fund Flow propagates in reverse—the payers at the end of the chain (insurance, government medical insurance, device/consumables procurement, patient out-of-pocket) are the true sources of funds. Drug and device sales translate into pharma R&D budgets, which then become CXO orders and upstream reagent purchases. Therefore, to judge industry health, first look at pharma R&D investment and the financing environment (Fed rate cuts directly affect Biotech financing); whereas the downstream medical device leaders and payers operate on the opposite logic—they benefit from cost controls and are virtually unaffected by patent cliffs, acting as the defensive anchor of the chain. Another major theme is innovation value realization: clinical data readouts, FDA/NMPA approvals, and MNC BD deals determine the valuation anchors of innovative pharma companies. Click on any segment to automatically filter the company list below.

Upstream · Tools, Raw Materials & OutsourcingMidstream · Innovative Drugs & Big PharmaDownstream · Devices, Payers & Distribution
UPSTREAM
→
MIDSTREAM
→
DOWNSTREAM
Product Flow → Reagents/Raw Materials / R&D & Manufacturing Services / Drugs / Patient Accessibility ← Fund Flow Insurance/Medicare Payouts / Drug Sales / BD Upfronts & Milestones / R&D Budgets / CXO Orders (Leading Indicators)
02

Company Profiles: 26 Companies Across Three Markets

Moat ratings are qualitative assessments (5-point scale: comprehensive evaluation of pipeline quality & clinical barriers, patents & access, cash flow quality, scale & globalization capabilities, and policy/volume procurement exposure). Biopharma is highly fragmented—big pharma is about "cash flow + patent cliffs", biotech is about "pipeline options + cash burn", and CXO is about "selling shovels". Profiles specify each company's attributes and core themes. Click on a card to view its complete profile.
03

ETF Tools: How to Capture Industry Beta Without Selecting Stocks

The risk of "single clinical events" for individual biopharma stocks is extremely high (a Phase III data readout can swing a Biotech by ±50% in a single day), and ETFs can effectively spread pipeline risk. US stocks are divided into "large-cap pharma (defensive)" and "small-cap biotech (offensive)"; A-Shares/HK stocks have multiple ETFs covering the two main themes of "innovative drugs" and "CXO". All three markets offer rich tools, making it the sector with the most comprehensive ETF options among major industries.

Market / Ticker Underlying Index Expense Ratio Structural Characteristics Applicable Scenarios
US: XBIOffensive S&P Biotechnology Select Industry Index (Equal Weight) 0.35% Equal-weighted, mainly small/mid-cap Biotech, highly sensitive to interest rates and M&A, high volatility Betting on Biotech valuation recovery and M&A waves in a rate cut cycle
US: IHI iShares U.S. Medical Devices Index 0.40% Device leaders like Medtronic and Abbott; more defensive than pharma, fewer patent cliffs Seeking medical exposure while avoiding drug pricing risks
US: XLV Health Care Select Sector SPDR Fund 0.08% Large-cap leaders like Eli Lilly and UnitedHealth; extremely low fees, strong defensive attributes Low-cost allocation to the US healthcare large-cap market
HK: 513280 Hang Seng Biotech Index (China Universal) 0.15% Lowest expense ratio tier; innovative drugs account for ~60%, CXO ~20%, balanced layout One-click allocation to the entire HK-listed innovative drugs + CXO value chain
HK: 520880 HK Stock Connect Innovative Drug Index (Hwabao) 0.5%+0.1% 100% innovative drug R&D targets, high purity and high elasticity Betting on the offensive exposure of HK-listed innovative drugs
A-Share: 159839 SZSE Bio-Pharma Index (China Universal) 0.5%+0.1% CXO and innovative drugs each account for ~50% weight, high sensitivity and strong elasticity Allocating to the A-share CXO + innovative drug dual themes
A-Share: 515120 CSI Innovative Drug Industry Index (GF Fund) 0.5%+0.1% Focuses on the A-share innovative drug value chain, prominent growth style A-share innovative drug theme pure play allocation
04

Decision Signals Calendar: What to Watch & When to Watch

The pricing of this value chain is highly "event-driven": clinical data, approvals, BD deals, and financial reports are the key milestones that re-value these assets. In order of importance, the first two signals determine the industry's funding environment and the global expansion narrative.

Quarterly · FOMC + Biotech Financing Data
Fed Interest Rates & Global Biotech Funding
Biotech is the quintessential "long-duration asset", with valuations highly sensitive to interest rates; a rate-cut cycle directly improves primary market financing and M&A environments, which in turn drives CXO orders. XBI is highly correlated with the interest rate path and serves as the master switch for judging the financial health of the entire innovative drug chain—early 2026 is in a rate-cut cycle, and the recovery of overseas funding is a common tailwind for CXO and Biotech.
Occasional · Company Announcements & Industry Databases
China Innovative Drug License-out (BD) Deals
Going global is the core path of "value release" for Chinese innovative drugs: total transaction value reached ~$135.7 billion in 2025 (157 deals). Focus on three levels—upfront payment scale (the direct source of cash flow, such as the record-breaking $1.25B deal between 3SBio and Pfizer), whether the counterparty is a TOP MNC (nearly 40% of BD value flows to China), and hot therapeutic areas (bispecific ADCs, oral GLPs, small nucleic acids, PD-1/VEGF). BD execution often brings single-day surges to the stock.
Annual · ASCO/ESMO/AACR/JPM Conferences
Global Academic Conferences & Key Clinical Data Readouts
"Clinical data is the research report": ASCO (May-June), ESMO (Q3), AACR, and the JPM Healthcare Conference are windows for concentrated data readouts and BD negotiations. From 2026 onwards, global Phase III clinical trials of multiple Chinese assets will see data readouts. Head-to-head superiority data can directly lift valuations, while failure breaks the investment thesis. This is the period of most intense Biotech volatility.
FDA/NMPA Approval Calendar (PDUFA)
Approval Decisions on Key Varieties
Approval is the final gate for turning pipelines into revenue. Track explicit PDUFA dates (such as Akeso's ivonescimab FDA decision), priority review, and breakthrough therapy designations. FDA tightening or criteria changes (which shocked the internationalization narrative in H2 2025) present systemic risks; approval opens commercial upside. Also focus on domestic medical insurance negotiations (NMPA) and their impact on domestic pricing and sales.
Quarterly · CXO Earnings & Order Guidance
CXO Backlog & Newly Signed Orders
CXO is the "shovel seller's thermometer" of the value chain's health: WuXi AppTec's backlog of ~¥60B (~1.3x of previous year's revenue) and Q1 net profit growth of +71.7% validate the cyclical recovery. Watch the growth rate of newly signed orders, the divergence between CDMO (especially GLP-1/ADC new molecules) and CRO, and capacity utilization. Note the increasing industry concentration—leaders thrive while small and mid-sized CXOs may lose momentum.
Occasional · US-China Policy Windows
Biosecure Act, Tariffs & Drug Pricing Policies
Geopolitics is a sword hanging over CXOs: The US Biosecure Act 2.0 has been enacted (removing direct naming of companies like WuXi, with the White House list to be finalized by the end of 2026); its progress determines the valuation discount of CXOs. Domestically, watch the scope of volume-based procurement (VBP), innovative drug pricing mechanism reforms (breaking pricing ceilings), and medical insurance negotiations—policy is both a risk and a catalyst.
05

Risk Matrix: Systemic vs Segment-specific

Systemic risks impact all segments; segment-specific risks can be hedged through portfolio structuring (e.g., balancing Biotech pipeline options with big pharma cash flows, hedging clinical risks of individual drug companies with CXO shovel sellers, and balancing innovative drug volatility with defensive device/distribution allocations).

Systemic Risks (Value Chain Co-resonance)

  1. Interest Rate & Financing Environment—Biotech is a long-duration asset; rising rates depress both valuation denominators and primary market financing, which propagates to CXO via R&D budget cuts. Fluctuations in rate-cut expectations are the biggest macro variable for the value chain.
  2. Geopolitics & Supply Chain—The US Biosecure Act, tariffs, and restrictions on the Chinese pharma supply chain directly impact CXO (high share of overseas revenue) and commercialization assumptions of globalizing Biotech; the final scope of the White House restricted list is a sword of Damocles.
  3. Drug Pricing & Payer Policies—US IRA drug price negotiations, Chinese volume procurement, and medical insurance negotiations continue to compress profit margins of existing varieties; although innovative drug pricing mechanisms are improving, the payer side remains the ceiling of industry returns.
  4. Falsification of the Expansion Narrative—Valuation anchors for Chinese innovative drugs are heavily dependent on "global peak sales × BD royalties." If the FDA tightens, global Phase III data disappoints, or MNCs return pipeline assets, the sector's internationalization premium will contract systemically (as witnessed in H2 2025).

Segment-specific Risks (Hedgeable Structure)

  1. Single Clinical/Approval Events—The value of Biotech is highly concentrated in a few pipeline assets; a Phase III failure or approval rejection can slash a stock price in half. This is the most idiosyncratic risk, requiring ETFs or diversified portfolios to mitigate.
  2. Patent Cliffs—Existing revenues of big pharma (like MNCs facing key product expirations) face generic/biosimilar substitution; this represents a reverse opportunity for domestic biosimilar developers (e.g., semaglutide's China patent expiring in 2026).
  3. GLP-1 Overcrowding—Weight loss drugs represent both a massive trend and a crowded trade: multi-target, oral, amylin, and other new directions are emerging, forcing latecomers to face head-to-head clinical efficacy comparison and pricing pressure; upstream peptide API manufacturers risk overcapacity after 2026.
  4. CXO Divergence & Capacity—Market recovery but the winner takes all; small and mid-sized CXOs face order deceleration and marginalization; geopolitical friction and RMB appreciation pose profit margin challenges for companies with high overseas exposure.